Clareo Health | Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
9–11
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Has not yet had coitarche and does not plan on becoming sexually active during the vaccination period
Participant or participant's legally acceptable representative can read, understand, and complete the electronic vaccination report card (eVRC).
You may not be if
Known allergy to any vaccine component
History of severe allergic reaction that required medical intervention
Thrombocytopenia or any coagulation disorder
Has a history of myocarditis or pericarditis
Has a history of a clinical or microbiological diagnosis of COVID-19 ≤90 days prior to Day 1 visit or history of multisystem inflammatory syndrome in children (MIS-C) at any time prior to Day 1 visit
Females only: participant is pregnant
Currently immunocompromised, or been diagnosed with immunodeficiency
Had a splenectomy
Receiving or has received immunosuppressive therapies within the last year
Received any immunoglobulin product or blood-derived product within 3 months
Received a marketed HPV vaccine or has participated in an HPV vaccine clinical trial
